Category Archives: Uncategorized

Federal Circuit affirms DC’s grant of SJ, finding Enzo’s claims invalid for lack of enablement

Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. et al. (Becton Dickinson (BD), GeneOhm, Aboott) Docket Nos. 2017-2498, -2499, -2545, -2546 (public opinion: July 25, 2019) Brief Summary:  DC grant of SJ for invalidity of Enzo’s claims for lack … Continue reading

Posted in Enablement, Uncategorized | Leave a comment

Federal Circuit affirms Board IPR decision invalidating design patents for obviousness

Kolcraft Enterprises, Inc. v. Graco Children’s Products, Inc. Docket No. 2018-1259-60 (IPR2016-00816, -00826) MOORE, REYNA, CHEN July 2, 2019 Brief summary:  Board IPR decision of invalidity of Kolcraft’s design patents affirmed as evidence regarding inventor’s date of conception was uncorroborated. … Continue reading

Posted in Conception and Reduction to Practice, Design Patents, Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Federal Circuit invalidates reissue patent invalid for lack of written description (WD)

Forum US, Inc. v. Flow Valve, LLC et al. (FC Docket No. 2018-1765; June 17, 2019) ~ Forum filed DJ action, DC granted SJ to Forum for lack of WD, FV appealed ~ U.S. 8,215,213 relates “to supporting assemblies” (“arbors”) … Continue reading

Posted in Reissue, Uncategorized, Written description | Leave a comment

USPTO IPR claim construction and obviousness determinations for network communications claims affirmed

Bradium Technologies LLC v. Andre Iancu (USPTO (Intervenor) Docket No. 2017-257, -2580 (IPR2016-00448, -00449) MOORE, REYNA, CHEN May 13, 2019 Brief summary: Board claim construction and obviousness determinations affirmed (e.g., no “clear and unambiguous definition limiting the term to only … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away, Uncategorized | Leave a comment

Fed. Cir. affirms PTAB IPR decision finding BTGs’s ZYTIGA® (abiratone) Orange Book ‘438 method of treatment patent invalid for obviousness

BTG Int. Ltd. and Janssen Biotech, Inc. et al. v. Amneal Pharmaceuticals LLC, et al. Docket Nos. 2019-1147, -1148. -1323, -1324, -1325 MOORE, WALLACH, CHEN May 14, 2019 Brief summary: PTAB IPR decision finding BTGs’s ZYTIGA® (abiratone) Orange Book ‘438 … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Ten Most Viewed Posts of 2017

1. Warsaw Orthopedic, Inc. / Medtronic Sofamor Danek USA, Inc. (“MSD”) et al. v. NuVasive, Inc. Docket No. 2013-1576, -1577 LOURIE, DYK, REYNA (C) June 3, 2016 On remand from SCOTUS, this decision affirmed DC/jury finding of induced infringement. The … Continue reading

Posted in Uncategorized | Leave a comment

Amgen Inc. et al. v. Sanofi, Regeneron et al.

Docket No. 2017-1480 PROST, TARANTO, HUGHES October 5, 2017 Brief summary: DC’s exclusion of post-priority-date evidence relating to whether a representative number of species were described in the patents’ specifications reversed and remanded; grant of permanent injunction against Sanofi therefore … Continue reading

Posted in Injunction, Uncategorized, Written description | Leave a comment